Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone de...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Paulfrench Dec. 4 at 7:26 PM

$TNYA Remember the 4-hour chart? We've returned to the resistance level formed by the bottom of the cloud... Our goal is to break through it...

0 · Reply

The1Albatross Dec. 4 at 6:36 PM

$TNYA Been in this one a few times. Looking for a greedy entry

0 · Reply

Stockley_Bulbousberries Dec. 4 at 4:17 PM

$TNYA Nice movement over the last few days

0 · Reply

stevenryl86 Dec. 4 at 3:16 PM

$TNYA if not this week then the news should Be on next week

1 · Reply

Paulfrench Dec. 3 at 9:16 PM

$TNYA And here's a very nice candlestick crossing the Tenkan-sen (+ 50MA ) line with a volume less than 2 times that of the previous day. 🎉For me, this is a pretty strong bullish signal; in my opinion, it mainly marks a return to the uptrend (in my opinion) Especially since it comes right after a VSA divergence...finally, some really good news, guys!✊️ Des bises a tous!🤗 P.S : I have a feeling the FDA's announcement shouldn't be too far off...but that's purely speculative.😇

3 · Reply

Paulfrench Dec. 3 at 9:09 AM

$TNYA I thought the $1.25 level would be more strongly defended by buyers, but that wasn't the case. However, yesterday's candlestick pattern still shows a bullish VSA divergence, indicating that buyers absorbed the downward pressure, which is a good sign for considering a rebound from the $1.16/$1.23 support zone

0 · Reply

GhostTrader11 Dec. 2 at 6:01 PM

$TNYA Long signal still in play, Trading sideways until news. Maybe a technical and/or risk off bounce. My 2 cents....

0 · Reply

Cel55 Dec. 2 at 3:15 PM

$TNYA “Will Tenaya Therapeutics attend a conference today? There is no announcement.”

2 · Reply

Conord91 Dec. 2 at 5:34 AM

$TNYA TN-401 data comes when?

1 · Reply

Iightning Dec. 2 at 2:31 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $TNYA **Contract:** Dec 19 $1C **Entry:** 0.79 **Exit:** 1.11 **Return:** **+40.61% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript

Nov 8, 2025, 11:25 AM EST - 26 days ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Nov 4, 2025, 5:30 PM EST - 4 weeks ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 4:05 PM EDT - 2 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 2, 2025, 4:05 PM EDT - 2 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Sep 18, 2025, 4:05 PM EDT - 2 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2025, 11:07 PM EDT - 3 months ago

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 3 months ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 31, 2025, 10:15 AM EDT - 3 months ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 8, 2025, 8:00 AM EDT - 4 months ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 7, 2025, 12:19 AM EDT - 4 months ago

Tenaya (TNYA) Q2 Loss Narrows 59%

Aug 6, 2025, 4:30 PM EDT - 4 months ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:30 AM EDT - 4 months ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 13, 2025, 8:30 AM EDT - 7 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 8 months ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 8 months ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 9 months ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 9 months ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 10, 2025, 4:05 PM EDT - 9 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 11:19 PM EST - 9 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Mar 3, 2025, 4:10 PM EST - 9 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Mar 3, 2025, 8:00 AM EST - 9 months ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 10 months ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 11 months ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 16, 2024, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Feb 26, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 3, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 2 years ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:19 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 7:50 AM EDT - 2 years ago

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

NKTX

Apr 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 20, 2023, 2:46 PM EDT - 2 years ago

Why This Nasdaq Stock Caught Fire This Week

Paulfrench Dec. 4 at 7:26 PM

$TNYA Remember the 4-hour chart? We've returned to the resistance level formed by the bottom of the cloud... Our goal is to break through it...

0 · Reply

The1Albatross Dec. 4 at 6:36 PM

$TNYA Been in this one a few times. Looking for a greedy entry

0 · Reply

Stockley_Bulbousberries Dec. 4 at 4:17 PM

$TNYA Nice movement over the last few days

0 · Reply

stevenryl86 Dec. 4 at 3:16 PM

$TNYA if not this week then the news should Be on next week

1 · Reply

Paulfrench Dec. 3 at 9:16 PM

3 · Reply

Paulfrench Dec. 3 at 9:09 AM

0 · Reply

GhostTrader11 Dec. 2 at 6:01 PM

$TNYA Long signal still in play, Trading sideways until news. Maybe a technical and/or risk off bounce. My 2 cents....

0 · Reply

Cel55 Dec. 2 at 3:15 PM

$TNYA “Will Tenaya Therapeutics attend a conference today? There is no announcement.”

2 · Reply

Conord91 Dec. 2 at 5:34 AM

$TNYA TN-401 data comes when?

1 · Reply

Iightning Dec. 2 at 2:31 AM

0 · Reply

Bullishstockwatch Dec. 1 at 9:06 PM

$TNYA back in ! Grabbed some shares at the last minute. We need some announcements soon 🙏

0 · Reply

Hereinbama35 Dec. 1 at 8:09 PM

$TNYA When is this going to hit $4? Asking for a friend.

1 · Reply

Cel55 Dec. 1 at 6:08 PM

$TNYA Our greatest luck is having you in this group. You share useful things with us, you tell us what might happen in advance, and you keep us from panicking. On behalf of everyone, I want to thank you, my friend.

3 · Reply

cheetohottaki Dec. 1 at 4:12 PM

$TNYA smfh

1 · Reply

NakedShort23skidoo Dec. 1 at 4:02 PM

$TNYA here comes the Wall Street Monday morning bank robbery. Wall Street just loves taking money from people like candy from a child

0 · Reply

trader2360 Dec. 1 at 1:34 AM

$TNYA this is the last time, i am posting this here

2 · Reply

Paulfrench Nov. 30 at 8:52 AM

$TNYA Friday's trading session was truncated, with only 4 hours of trading, which is unfortunate as we had a strong buy signal! To analyze the chart, we therefore need to reduce the time scale to 4 hours.

1 · Reply